Zevra Therapeutics (ZVRA) Leases (2018 - 2025)
Zevra Therapeutics (ZVRA) has disclosed Leases for 9 consecutive years, with $1.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Leases rose 15050.0% year-over-year to $1.2 million, compared with a TTM value of $1.2 million through Dec 2025, up 15050.0%, and an annual FY2025 reading of $1.2 million, up 15050.0% over the prior year.
- Leases was $1.2 million for Q4 2025 at Zevra Therapeutics, down from $1.3 million in the prior quarter.
- Across five years, Leases topped out at $1.6 million in Q1 2025 and bottomed at $8000.0 in Q4 2024.
- Average Leases over 5 years is $925900.0, with a median of $1.1 million recorded in 2022.
- The sharpest move saw Leases tumbled 94.63% in 2024, then soared 15050.0% in 2025.
- Year by year, Leases stood at $1.1 million in 2021, then fell by 13.41% to $988000.0 in 2022, then plummeted by 84.92% to $149000.0 in 2023, then crashed by 94.63% to $8000.0 in 2024, then skyrocketed by 15050.0% to $1.2 million in 2025.
- Business Quant data shows Leases for ZVRA at $1.2 million in Q4 2025, $1.3 million in Q3 2025, and $1.5 million in Q2 2025.